Impact of somatic mutations on recurrence free survival (RFS) and overall survival (OS) for resected nonsmall cell lung cancer (NSCLC): results from the Japan Molecular Epidemiology for lung cancer study (JME).

被引：0
|
作者：
Tamiya, Akihiro
Koh, Yasuhiro
Kubo, Akihito
Ando, Masahiko
Isa, Shun-ichi
Saka, Hideo
Yoshimoto, Naoki
Serizawa, Masakuni
Takeo, Sadanori
Adachi, Hirofumi
Tagawa, Tsutomu
Kawashima, Osamu
Yamashita, Motohiro
Kataoka, Kazuhiko
Ichinose, Yukito
Takeuchi, Yukiyasu
Watanabe, Katsuya
Matsumura, Akihide
Kawaguchi, Tomoya
机构：
[1] Natl Hosp Org Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
[2] Wakayama Med Univ, Wakayama, Japan
[3] Aichi Med Univ, Sch Med, Div Resp Med & Allergol, Nagakute, Aichi, Japan
[4] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan
[5] Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan
[6] Osaka City Univ, Grad Sch Med, Dept Clin Oncol, Osaka, Japan
[7] Shizuoka Canc Ctr Res Inst, Div Drug Discovery & Dev, Nagaizumi, Shizuoka, Japan
[8] Natl Hosp Org Kyushu Med Ctr, Fukuoka, Fukuoka, Japan
[9] Hokkaido Canc Ctr, Natl Hosp Org, Dept Thorac Surg, Sapporo, Hokkaido, Japan
[10] Natl Hosp Org Nagasaki Med Ctr, Omura, Japan
[11] Natl Hosp Org Shibukawa Med Ctr, Shibukawa, Japan
[12] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[13] Natl Hosp Org Iwakuni Clin Ctr, Iwakuni, Japan
[14] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Fukuoka, Japan
[15] Natl Hosp Org Toneyama Natl Hosp, Toyonaka, Osaka, Japan
[16] Natl Hosp Org Yokohama Med Ctr, Yokohama, Kanagawa, Japan
[17] Natl Hosp Org Kinki Chuo Chest Med Ctr, Osaka, Japan
[18] Osaka City Univ, Grad Sch Med, Dept Resp Med, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8549
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8549
引用
收藏
页数：2
相关论文
共 50 条
  • [41] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, L.
    De Castro Carpeno, J.
    Chouaid, C.
    Vergnenegre, A.
    Bischoff, H. G.
    Walzer, S.
    VALUE IN HEALTH, 2011, 14 (03) : A177 - A178
  • [42] Adjuvant chemotherapy improves overall and disease-free survival in non-small cell lung cancer (NSCLC): results of the IALT trial
    Le Chevalier, T
    Kozlowski, M
    Pignon, JP
    Bergman, B
    Orlowski, T
    Pirker, R
    Le Pechoux, C
    Tarayre, M
    Dunant, A
    LUNG CANCER, 2004, 46 : S13 - S13
  • [43] Joint model of longitudinal tumor size and overall survival (OS) in non-small cell lung cancer (NSCLC): A Bayesian approach
    Al-Huniti, Nidal
    Xu, Hongmei
    Zhou, Diansong
    Edlund, Helena
    Aksenov, Sergey
    Helmlinger, Gabriel
    Dunyak, James
    CANCER RESEARCH, 2018, 78 (13)
  • [44] Early radiological response (ERR) as predictor of overall survival in non small cell lung cancer (NSCLC) patients with EGFR mutations
    Salvador Coloma, C.
    Nino, O. M.
    Gomez Codina, J.
    Escoin Perez, C.
    Palanca, S.
    Akhoundova Sanoyan, D.
    Melian, M.
    Montalar, J.
    Juan, O.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S127 - S127
  • [45] Bayesian formulation of a joint model of longitudinal tumor size and overall survival (OS) in Non-Small Cell Lung Cancer (NSCLC)
    Al-Huniti, Nidal
    Dunyak, James
    Aksenov, Sergey
    Zhou, Diansong
    Xu, Hongmei
    Masson, Eric
    Helmlinger, Gabriel
    Edlund, Helena
    Stanski, Donald
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S141 - S141
  • [46] Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression
    Genova, C.
    Rijavec, E.
    Rossi, G.
    Biello, F.
    Barletta, G.
    Tagliamento, M.
    Grossi, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Overall Survival (OS) of Pathological N2 Non-Small Cell Lung Cancer (NSCLC) After Surgical Resection
    Bourdages-Pageau, E.
    Vieira, A.
    Labbe, C.
    Figueroa, P. Ugalde
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2233 - S2233
  • [48] Overall Survival (OS) of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) After Negative Invasive Mediastinal Staging
    Bourdages-Pageau, E.
    Vieira, A.
    Labbe, C.
    Figueroa, P. Ugalde
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2233 - S2234
  • [49] Modified Glasgow Prognostic Score at Recurrence Predicts Poor Survival in Resected Non-Small Cell Lung Cancer (NSCLC) Patients
    Lv, Yongbin
    Pan, Yinghua
    Dong, Changxia
    Liu, Peiji
    Zhang, Chunping
    Xing, Dong
    MEDICAL SCIENCE MONITOR, 2017, 23 : 3780 - 3788
  • [50] PROGNOSTIC FACTORS OF DISEASE RECURRENCE AND OVERALL SURVIVAL IN ELDERLY VERSUS YOUNG PATIENTS IN SURGICALLY RESECTED NON SMALL CELL LUNG CANCER
    Al-Alao, B.
    Mc Govern, E. N.
    Young, V. N.
    O'Byrne, K.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S48 - S48
12345